- Home
- SLDP vs LYEL Comparison
SLDP vs LYEL Comparison
Compare SLDP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- LYEL
- Stock Information
- Founded
- SLDP 2011
- LYEL 2018
- Country
- SLDP United States
- LYEL United States
- Employees
- SLDP N/A
- LYEL N/A
- Industry
- SLDP Electrical Products
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- LYEL Health Care
- Exchange
- SLDP Nasdaq
- LYEL Nasdaq
- Market Cap
- SLDP 209.3M
- LYEL 207.7M
- IPO Year
- SLDP N/A
- LYEL 2021
- Fundamental
- Price
- SLDP $1.09
- LYEL $0.45
- Analyst Decision
- SLDP Buy
- LYEL Sell
- Analyst Count
- SLDP 3
- LYEL 2
- Target Price
- SLDP $2.67
- LYEL $1.00
- AVG Volume (30 Days)
- SLDP 2.0M
- LYEL 680.4K
- Earning Date
- SLDP 05-06-2025
- LYEL 05-13-2025
- Dividend Yield
- SLDP N/A
- LYEL N/A
- EPS Growth
- SLDP N/A
- LYEL N/A
- EPS
- SLDP N/A
- LYEL N/A
- Revenue
- SLDP $20,139,000.00
- LYEL $61,000.00
- Revenue This Year
- SLDP $40.13
- LYEL N/A
- Revenue Next Year
- SLDP $54.82
- LYEL N/A
- P/E Ratio
- SLDP N/A
- LYEL N/A
- Revenue Growth
- SLDP 15.68
- LYEL N/A
- 52 Week Low
- SLDP $0.68
- LYEL $0.39
- 52 Week High
- SLDP $2.70
- LYEL $2.88
- Technical
- Relative Strength Index (RSI)
- SLDP 45.56
- LYEL 39.21
- Support Level
- SLDP $1.10
- LYEL $0.42
- Resistance Level
- SLDP $1.20
- LYEL $0.49
- Average True Range (ATR)
- SLDP 0.06
- LYEL 0.04
- MACD
- SLDP 0.01
- LYEL 0.00
- Stochastic Oscillator
- SLDP 40.09
- LYEL 25.04
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.